ArticleCase reports in neurology
Chorea as a Non-Thrombotic Manifestation in an Adolescent with Systemic Lupus Erythematosus, Antiphospholipid Syndrome and Heterozygous Prothrombin G20210A Gene Mutation: A Case Report.
Article in Case reports in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chorea is a rare movement disorder in the context of systemic lupus erythematosus (SLE). Although basal ganglia thrombosis, autoimmune injury or neuronal direct lesion have been proposed as possible explanations, its mechanism is still unknown. It is important to understand its pathogenesis so that the best treatments can be identified. Case Presentation: A 12-year-old female adolescent with choreoathetoid movements of the trunk and four limbs, slurred speech, hypophonia and orofacial dyskinesia with 14 days of evolution. Brain magnetic resonance imaging revealed recent subcortical ischemic lesions in both frontal and parietal lobes. Basal ganglia lesions were not found. She started acetylsalicylic acid (ASA) and tetrabenazine, with chorea improvement. Transcranial Doppler ultrasound identified a microembolic sign between the left middle cerebral and anterior cerebral arteries. Therefore, ASA was switched to enoxaparin. Antinuclear antibodies and lupus anticoagulant (LAC) antibody were positive, with heterozygous prothrombin G20210A gene mutation being found. Five-day methylprednisolone pulses 1 g/day were performed, followed by prednisolone 60 mg/day. Intravenous immunoglobulin was administered, and hydroxychloroquine was initiated. Due to progressive microscopic hematuria and non-nephrotic proteinuria, a kidney biopsy was performed, being compatible with class V lupus nephritis. Consequently, mycophenolate mofetil and enalapril were started. Chorea resolved 5 days later. After discharge, LAC remained positive, but no more neurologic symptoms occurred. Conclusions: Basal ganglia thrombosis does not seem to be the most likely mechanism of SLE-related chorea. Antiphospholipid antibodies alone do not seem to be enough to trigger chorea. Further studies are needed to clarify the mechanisms that trigger this movement disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.